Oronsky B, Ma PC, Morgensztern D, Carter CA. Nothing but net: a review of neuroendocrine tumors and carcinomas. Neoplasia (New York, N.Y.). 2017;19(12):991–1002. https://doi.org/10.1016/j.neo.2017.09.002

Eriksson B, Klöppel G, Krenning E, Ahlman H, Plöckinger U, Wiedenmann B, Arnold R, Auernhammer C, Körner M, Rindi G, Wildi S, Frascati Consensus Conference participants. Consensus guidelines for the management of patients with digestive neuroendocrine tumors–well-differentiated jejunal-ileal tumor/carcinoma. Neuroendocrinology. 2008;87(1):8–19. https://doi.org/10.1159/000111034.

Article  Google Scholar 

Faggiano A, Lo Calzo F, Pizza G, Modica R, Colao A. The safety of available treatments options for neuroendocrine tumors. Expert Opin Drug Saf. 2017;16(10):1149–61. https://doi.org/10.1080/14740338.2017.1354984.

Article  Google Scholar 

Kwekkeboom DJ, Krenning EP, Lebtahi R, Komminoth P, Kos-Kudła B, de Herder WW, Plöckinger U. ENETS Consensus guidelines for the standards of care in neuroendocrine tumors: peptide receptor radionuclide therapy with radiolabeled somatostatin analogs. Neuroendocrinology. 2009;90(2):220–6. https://doi.org/10.1159/000225951.

Article  Google Scholar 

Eberlein U, Nowak C, Bluemel C, Buck AK, Werner RA, Scherthan H, Lassmann M. DNA damage in blood lymphocytes in patients after (177)Lu peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging. 2015;42(11):1739–49. https://doi.org/10.1007/s00259-015-3083-9.

Article  Google Scholar 

Williams LE, DeNardo GL, Meredith RF. Targeted radionuclide therapy. Med Phys. 2008;35(7Part1):3062–8. https://doi.org/10.1118/1.2938520.

Article  Google Scholar 

Baskar R, Lee KA, Yeo R, Yeoh K-W. Cancer and radiation therapy: current advances and future directions. Int J Med Sci. 2012;9(3):193–9. https://doi.org/10.7150/ijms.3635.

Article  Google Scholar 

Teunissen JJ, Kwekkeboom DJ, Valkema R, Krenning EP. Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours. Endocr Relat Cancer. 2011;18(Suppl 1):S27–51. https://doi.org/10.1530/ERC-10-0282.

Article  Google Scholar 

Severi S, Grassi I, Nicolini S, Sansovini M, Bongiovanni A, Paganelli G. Peptide receptor radionuclide therapy in the management of gastrointestinal neuroendocrine tumors: efficacy profile, safety, and quality of life. Onco Targets Ther. 2017;10:551–7. https://doi.org/10.2147/ott.s97584.

Article  Google Scholar 

Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, Feelders RA, van Aken MO, Krenning EP. Treatment with the radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3] octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008;26(13):2124–30. https://doi.org/10.1200/jco.2007.15.2553.

Article  Google Scholar 

Bodei L, Kidd M, Paganelli G, Grana CM, Drozdov I, Cremonesi M, Lepensky C, Kwekkeboom DJ, Baum RP, Krenning EP, Modlin IM. Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors. Eur J Nucl Med Mol Imaging. 2014;42(1):5–19. https://doi.org/10.1007/s00259-014-2893-5.

Article  Google Scholar 

Fröss-Baron K, Garske-Román U, Welin S, Granberg D, Eriksson B, Khan T, Sandström M, Sundin A. 177Lu-DOTATATE therapy of advanced pancreatic neuroendocrine tumors heavily pretreated with chemotherapy; analysis of outcome, safety and their determinants. Neuroendocrinology. 2020;111:330–43. https://doi.org/10.1159/000506746.

Article  Google Scholar 

Svensson J, Mölne J, Forssell-Aronsson E, Konijnenberg M, Bernhardt P. Nephrotoxicity profiles and threshold dose values for [177Lu]-DOTATATE in nude mice. Nucl Med Biol. 2012;39(6):756–62. https://doi.org/10.1016/j.nucmedbio.2012.02.003.

Article  Google Scholar 

Bergsma H, Konijnenberg MW, Kam BLR, Teunissen JJM, Kooij PPM, de Herder WW, Franssen GJH, van Eijck CHJ, Krenning EP, Kwekkeboom DJ. Subacute haematotoxicity after PRRT with 177Lu-DOTA-octreotate: prognostic factors, incidence and course. Eur J Nucl Med Mol Imaging. 2015;43(3):453–63. https://doi.org/10.1007/s00259-015-3193-4.

Article  Google Scholar 

Swärd C, Bernhardt P, Ahlman H, Wängberg B, Forssell-Aronsson E, Larsson M, Svensson J, Rossi-Norrlund R, Kölby L. [177Lu-DOTA0-Tyr3]-octreotate treatment in patients with disseminated gastroenteropancreatic neuroendocrine tumors: the value of measuring absorbed dose to the kidney. World J Surg. 2010;34(6):1368–72. https://doi.org/10.1007/s00268-009-0387-6.

Article  Google Scholar 

Valkema R, Pauwels SA, Kvols Lk, Kwekkeboom DJ, Jamar F, de Jong M, Barone R, Walrand S, Kooij PPm, Bakker WH, Lasher J, Krenning EP. Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate. J Nucl Med Off Publ Soc Nucl Med. 2005;46(Suppl 1):83S91S. https://doi.org/10.2967/jnumed.104.034165.

Article  Google Scholar 

Haug AR. PRRT of neuroendocrine tumors: individualized dosimetry or fixed dose scheme? EJNMMI Res. 2020. https://doi.org/10.1186/s13550-020-00623-3.

Article  Google Scholar 

Sundlöv A, Sjögreen-Gleisner K, Svensson J, Ljungberg M, Olsson T, Bernhardt P, Tennvall J. Individualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry. Eur J Nucl Med Mol Imaging. 2017;44(9):1480–9. https://doi.org/10.1007/s00259-017-3678-4.

Article  Google Scholar 

Marin G, Vanderlinden B, Karfis I, Guiot T, Wimana Z, Reynaert N, Vandenberghe S, Flamen P. A dosimetry procedure for organs-at-risk in 177Lu peptide receptor radionuclide therapy of patients with neuroendocrine tumours. Physic Med. 2018;56:41–9. https://doi.org/10.1016/j.ejmp.2018.11.001.

Article  Google Scholar 

Chicheportiche A, Ben-Haim S, Grozinsky-Glasberg S, Oleinikov K, Meirovitz A, Gross DJ, Godefroy J. Dosimetry after peptide receptor radionuclide therapy: impact of reduced number of post-treatment studies on absorbed dose calculation and on patient management. EJNMMI Phys. 2020. https://doi.org/10.1186/s40658-020-0273-8.

Article  Google Scholar 

Chicheportiche A, Grozinsky-Glasberg S, Gross DJ, Krausz Y, Salmon A, Meirovitz A, Freedman N, Godefroy J. Predictive power of the post-treatment scans after the initial or first two courses of [177Lu]-DOTA-TATE. EJNMMI Phys. 2018. https://doi.org/10.1186/s40658-018-0234-7.

Article  Google Scholar 

Hänscheid H, Lapa C, Buck AK, Lassmann M, Werner RA. Dose mapping after endoradiotherapy with 177Lu-DOTATATE/DOTATOC by a Single measurement after 4 days. J Nucl Med Off Publ Soc Nucl Med. 2018;59(1):75–81. https://doi.org/10.2967/jnumed.117.193706.

Article  Google Scholar 

Willowson KP, Eslick E, Ryu H, Poon A, Bernard EJ, Bailey DL. Feasibility and accuracy of single time point imaging for renal dosimetry following 177Lu-DOTATATE (“Lutate”) therapy. EJNMMI Phys. 2018. https://doi.org/10.1186/s40658-018-0232-9.

Article  Google Scholar 

Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med Off Publ Soc Nucl Med. 2005;46(6):1023–7.

Google Scholar 

Buijs WCAM, Oyen WJG, Dams EThM, Boerman OC, Siegel JA, Claessens RAMJ, van der Meer JWM, Corstens FHM. Dynamic distribution and dosimetric evaluation of human non-specific immunoglobulin G labelled with 111In or 99Tcm. Nucl Med Commun. 1998;19(8):743–52. https://doi.org/10.1097/00006231-199808000-00004.

Article  Google Scholar 

Knoll GF (2010) Radiation Detection and Measurement 4th Edition. Wiley, ISBN: 978-0-470-13148-0

Bodei L, Mueller-Brand J, Baum RP, Pavel ME, Hörsch D, O’Dorisio MS, O’Dorisio TM, O’Dorisiol TM, Howe JR, Cremonesi M, Kwekkeboom DJ, Zaknun JJ. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2013;40(5):800–16. https://doi.org/10.1007/s00259-012-2330-6.

Article  Google Scholar 

Jackson PA, Beauregard JM, Hofman MS, Kron T, Hogg A, Hicks RJ. An automated voxelized dosimetry tool for radionuclide therapy based on serial quantitative SPECT/CT imaging. Med Phys. 2013;40(11): 112503. https://doi.org/10.1118/1.4824318.

Article  Google Scholar 

Das S, Al-Toubah T, El-Haddad G, Strosberg J. 177Lu-DOTATATE for the treatment of gastroenteropancreatic neuroendocrine tumors. Expert Rev Gastroenterol Hepatol. 2019;13(11):1023–31. https://doi.org/10.1080/17474124.2019.1685381.

Article  Google Scholar 

Abuqbeitah M, Demir M, Uslu-Beşli L, Yeyin N, Sönmezoğlu K. Blood clearance and occupational exposure for 177Lu-DOTATATE compared to 177Lu-PSMA radionuclide therapy. Radiat Environ Biophys. 2018;57(1):55–61. https://doi.org/10.1007/s00411-017-0721-6.

Article  Google Scholar 

Zhao W, Esquinas PL, Frezza A, Hou X, Beauregard JM, Celler A. Accuracy of kidney dosimetry performed using simplified time activity curve modelling methods: a 177Lu-DOTATATE patient study. Phys Med Biol. 2019;64(17):175006. https://doi.org/10.1088/1361-6560/ab3039. PMID: 31287093.

Article  Google Scholar 

Mora-Ramirez E, Santoro L, Cassol E, Ocampo-Ramos JC, Clayton N, Kayal G, Chouaf S, Trauchessec D, Pouget J, Kotzki P, Deshayes E, Bardiès M. Comparison of commercial dosimetric software platforms in patients treated with 177 Lu-DOTATATE for peptide receptor radionuclide therapy. Med Phys. 2021;47(9):4602–15. https://doi.org/10.1002/mp.14375.

Article  Google Scholar 

Kupitz D, Wetz C, Wissel H, Wedel F, Apostolova I, Wallbaum T, Ricke J, Amthauer H, Grosser OS. Software-assisted dosimetry in peptide receptor radionuclide therapy with 177Lutetium-DOTATATE for various imaging scenarios. PLoS ONE. 2017;12(11):e0187570. https://doi.org/10.1371/journal.pone.0187570. PMID:29117243; PMCID:PMC5679636.

Article  Google Scholar 

Brans B, Bodei L, Giammarile F, Linden O, Luster M, Oyen WJG, Tennvall J. Clinical radionuclide therapy dosimetry: the quest for the Holy Gray. Eur J Nucl Med Mol Imaging. 2007;34(5):772–86. https://doi.org/10.1007/s00259-006-0338-5. Epub 2007 Jan 30 PMID: 17265043.

Article  Google Scholar 

Brosch-Lenz J, Ke S, Wang H, Frey E, Dewaraja YK, Sunderland J, Uribe C. An international study of factors affecting variability of dosimetry calculations, part 2: overall variabilities in absorbed dose. J Nucl Med. 2023;64(7):1109–16. https://doi.org/10.2967/jnumed.122.265094. Epub 2023 Apr 6. PMID: 37024302; PMCID: PMC10315703.

Article  Google Scholar 

Gear JI, Cox MG, Gustafsson J, Gleisner KS, Murray I, Glatting G, Konijnenberg M, Flux GD. EANM practical guidance on uncertainty analysis for molecular radiotherapy absorbed dose calculations. Eur J Nucl Med Mol Imaging. 2018;45(13):2456–74. https://doi.org/10.1007/s00259-018-4136-7. Epub 2018 Sep 14. PMID: 30218316; PMCID: PMC6208822.

Article  Google Scholar 

Santoro L, Pitalot L, Trauchessec D, Mora-Ramirez E, Kotzki PO, Bardiès M, Deshayes E. Clinical implementation of PLANET® Dose for dosimetric assessment after [177Lu]Lu-DOTA-TATE: comparison with Dosimetry Toolkit® and OLINDA/EXM® V1.0. EJNMMI Res. 2021;11(1):3. https://doi.org/10.1186/s13550-020-00737-8. PMID: 33499762; PMCID: PMC8756823.

Article  Google Scholar 

Huizing DMV, Peters SMB, Versleijen MWJ, Martens E, Verheij M, Sinaasappel M, Stokkel MPM, de Wit-van der Veen BJ. A head-to-head comparison between two commercial software packages for hybrid dosimetry after peptide receptor radionuclide therapy. EJNMMI Phys. 2020;7(7):1–84. https://doi.org/10.1186/s40658-020-00308-9. PMID: 33287811; PMCID: PMC7722165.

Article  Google Scholar 

Wehrmann C, Senftleben S, Zachert C, Müller D, Baum RP. Results of individual patient dosimetry in peptide receptor radionuclide therapy with 177Lu DOTA-TATE and 177Lu DOTA-NOC. Cancer Biother Radiopharm. 2007;22(3):406–16. https://doi.org/10.1089/cbr.2006.325. PMID: 17523894.

Article  Google Scholar 

Esser JP, Krenning EP, Teunissen JJM, Kooij PPM, van Gameren ALH, Bakker WH, Kwekkeboom DJ. Comparison of [177Lu-DOTA0, Tyr3]octreotate and [177Lu-DOTA0, Tyr3] octreotide: which peptide is preferable for PRRT? Eur J Nucl Med Mol Imaging. 2006;33(11):1346–51. https://doi.org/10.1007/s00259-006-0172-9. Epub 2006 Aug 8 PMID: 16896889.

Article  Google Scholar 

Schüler E, Österlund A, Forssell-Aronsson E. The amount of injected 177Lu-octreotate strongly influences biodistribution and dosimetry in C57BL/6N mice. Acta Oncol. 2015;55(1):68–76. https://doi.org/10.3109/0284186X.2015.1027001. Epub 2015 Apr 1 PMID: 25831737.

Article